Guoren Zhou

1.7k total citations
88 papers, 1.0k citations indexed

About

Guoren Zhou is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Guoren Zhou has authored 88 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 35 papers in Pulmonary and Respiratory Medicine and 34 papers in Oncology. Recurrent topics in Guoren Zhou's work include Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Treatments and Mutations (13 papers) and RNA modifications and cancer (13 papers). Guoren Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Treatments and Mutations (13 papers) and RNA modifications and cancer (13 papers). Guoren Zhou collaborates with scholars based in China, United States and Singapore. Guoren Zhou's co-authors include Hongping Xia, Jinjun Ye, Haojun Xu, Ying Fang, Lei Sun, Zhi Zhang, Qi Sun, Chengfei Zhang, Lin Xu and Yinhua Liu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Catalysis and Annals of Oncology.

In The Last Decade

Guoren Zhou

77 papers receiving 1.0k citations

Peers

Guoren Zhou
Xiangyu Che China
Chundong Gu China
Fuxiang Zhou China
Runsen Jin China
Yajin Chen China
Xiwei Ding China
Zuli Yang China
Haoran Li China
Qingfang Li China
Sachin Gopalkrishna Pai United States
Xiangyu Che China
Guoren Zhou
Citations per year, relative to Guoren Zhou Guoren Zhou (= 1×) peers Xiangyu Che

Countries citing papers authored by Guoren Zhou

Since Specialization
Citations

This map shows the geographic impact of Guoren Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guoren Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guoren Zhou more than expected).

Fields of papers citing papers by Guoren Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guoren Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guoren Zhou. The network helps show where Guoren Zhou may publish in the future.

Co-authorship network of co-authors of Guoren Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Guoren Zhou. A scholar is included among the top collaborators of Guoren Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guoren Zhou. Guoren Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Guoren, Chuanli Ren, Xiaoshi Zhang, et al.. (2025). Innovative upcycling of polyesters and polycarbonates via manganese-catalyzed hydrogenolysis. Journal of Catalysis. 446. 116060–116060. 1 indexed citations
2.
Liu, Ying, Dayong Gu, Yatian Liu, et al.. (2024). Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer. International Immunopharmacology. 141. 112939–112939. 1 indexed citations
3.
4.
5.
Ma, Zhifei, Hao Chen, Zhijun Xia, et al.. (2023). Energy stress-induced circZFR enhances oxidative phosphorylation in lung adenocarcinoma via regulating alternative splicing. Journal of Experimental & Clinical Cancer Research. 42(1). 169–169. 11 indexed citations
6.
Liu, Ying L., Huanhuan Sha, Weiwei Peng, et al.. (2023). To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Journal of Cancer Research and Clinical Oncology. 149(12). 10027–10040. 11 indexed citations
7.
Huang, Zhongxi, Qian Shen, Fu Chan, et al.. (2023). Glutathione depletion based Pt(IV) hybrid mesoporous organosilica delivery system to conquer cisplatin chemoresistance: A “one stone three birds” strategy. Chinese Chemical Letters. 35(10). 109450–109450. 6 indexed citations
8.
Peng, Weiwei, Chengyun Yao, Zhi Zhang, et al.. (2023). Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC. Frontiers in Oncology. 13. 1120278–1120278. 10 indexed citations
9.
Wu, Yuan, Xuefeng Zhou, Weiqing Zhao, et al.. (2023). Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial. Investigational New Drugs. 41(6). 825–833. 2 indexed citations
10.
Liu, Ying, Huanhuan Sha, Yue Chen, et al.. (2023). A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs. Cancer Immunology Immunotherapy. 72(12). 4355–4365. 3 indexed citations
11.
Liu, Yixuan, Qi Sun, Chengfei Zhang, et al.. (2023). STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages. iScience. 26(8). 107376–107376. 21 indexed citations
12.
Cai, Hongzhou, Hongcheng Lu, Weizhang Xu, et al.. (2022). LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer. Cancers. 14(19). 4740–4740. 13 indexed citations
13.
14.
15.
Zhang, Quanli, Run Shi, Yongkang Bai, et al.. (2021). Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma. Cancer Communications. 41(6). 492–510. 26 indexed citations
16.
Wang, Yongsheng, Feng Jiang, Ruixue Xia, et al.. (2021). Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis. Frontiers in Oncology. 11. 701171–701171. 8 indexed citations
17.
Zhang, Zhiying, Mengnan Du, Dayong Gu, et al.. (2021). 1378P A single-center, prospective, open-label, single-arm trial of sintilimab with paclitaxel and carboplatin as a neoadjuvant therapy for esophageal squamous carcinoma. Annals of Oncology. 32. S1042–S1043. 6 indexed citations
18.
Feng, J., Bo Shen, Li Deng, et al.. (2017). Real world data about clinical efficacy and safety of apatinib in the treatment of advanced gastric cancer. Annals of Oncology. 28. v237–v237. 2 indexed citations
19.
Ye, Jinjun, Zhi Zhang, Lei Sun, et al.. (2016). miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Molecular BioSystems. 12(11). 3417–3424. 46 indexed citations
20.
Ye, Jinjun, Guoren Zhou, Zhi Zhang, et al.. (2016). Poly (C)-binding protein 2 (PCBP2) promotes the progression of esophageal squamous cell carcinoma (ESCC) through regulating cellular proliferation and apoptosis. Pathology - Research and Practice. 212(8). 717–725. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangyu Che Breakdown of academic impact, for papers by Chundong Gu Breakdown of academic impact, for papers by Fuxiang Zhou Breakdown of academic impact, for papers by Runsen Jin Breakdown of academic impact, for papers by Yajin Chen Breakdown of academic impact, for papers by Xiwei Ding Breakdown of academic impact, for papers by Zuli Yang Breakdown of academic impact, for papers by Haoran Li Breakdown of academic impact, for papers by Qingfang Li Breakdown of academic impact, for papers by Sachin Gopalkrishna Pai
Rankless by CCL
2026